AZD 2858
Alternative Names: AZD2858Latest Information Update: 18 Nov 2004
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Oct 2004 Discontinued - Preclinical for Alzheimer's disease in Europe (unspecified route)
- 10 Oct 2003 Preclinical trials in Alzheimer's disease in Europe (unspecified route)